Skip to main content
TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · IEX Real-Time Price · USD
8.55
+0.26 (3.14%)
At close: May 31, 2024, 4:00 PM
8.78
+0.23 (2.69%)
After-hours: May 31, 2024, 4:04 PM EDT

TScan Therapeutics Revenue

TScan Therapeutics had revenue of $14.81M in the twelve months ending March 31, 2024, down -14.47% year-over-year. Revenue in the quarter ending March 31, 2024 was $566.00K, a -91.68% decrease year-over-year. In the year 2023, TScan Therapeutics had annual revenue of $21.05M with 55.52% growth.

Revenue (ttm)
$14.81M
Revenue Growth
-14.47%
P/S Ratio
30.51
Revenue / Employee
$92,000
Employees
161
Market Cap
451.98M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202321.05M7.51M55.52%
Dec 31, 202213.54M3.39M33.47%
Dec 31, 202110.14M9.06M834.65%
Dec 31, 20201.09M--
Dec 31, 20190--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Bioventus 522.74M
ZimVie 350.20M
Voyager Therapeutics 119.04M
Editas Medicine 69.41M
Jin Medical International 19.82M
Oculis Holding AG 995.46K
Revenue Rankings

TCRX News

More News